Trenchant BioSystems and Invetech announced a collaboration to commercialize AutoCell, a fully automated cell and gene therapy (CGT) manufacturing platform that could enable point‑of‑care production. Internal and independent testing suggests AutoCell may reduce or eliminate ex‑vivo expansion steps and generate T cells from a single whole‑blood draw, which the companies say could shrink costs and timelines. Invetech will provide engineering, development and manufacturing support, with Trenchant planning early access for partners in 2027 and full commercial release later that year. One‑sentence clarification: point‑of‑care CGT manufacturing aims to decentralize production by enabling hospitals or regional centers to produce autologous or allogeneic cell therapies without traditional centralized CDMO infrastructure. Why it matters: validated, automated point‑of‑care platforms could dramatically expand patient access, reduce logistics complexity, and alter supply models for autologous therapies if regulatory and quality systems scale accordingly.